头孢地尔:治疗多重耐药革兰阴性菌感染的新型铁载体头孢菌素
头孢地尔是一种新型铁载体头孢菌素,通过与细胞外游离铁离子结合形成复合物,经外膜转运进入菌体,抑制细胞壁合成发挥杀菌作用。体外及体内研究显示其对多种临床相关多重耐药革兰阴性菌有活性。
要点
- 头孢地尔对多种临床相关多重耐药革兰阴性菌有活性。
- FDA基于APEKS-cUTI、APEKS-NP和CREDIBLE-CR试验批准其适应证。
- CREDIBLE-CR中头孢地尔组全因死亡率高于最佳可用治疗组。
核心结论
- 头孢地尔对多重耐药革兰阴性菌所致复杂性尿路感染和医院获得性肺炎显示非劣效性,但严重感染中全因死亡率高于最佳可用治疗。
研究设计与样本
- 本文为综述,汇总头孢地尔的作用机制、体外和体内数据、药代动力学、药效学、药敏试验、疗效和安全性数据。
主要发现
- 头孢地尔与细胞外游离铁离子结合形成复合物,经外膜转运进入菌体,通过抑制细胞壁合成发挥杀菌活性。
- 体外和体内研究显示头孢地尔对多种临床相关多重耐药革兰阴性菌有活性。
- APEKS-cUTI中头孢地尔治疗多重耐药革兰阴性菌所致复杂性尿路感染对亚胺培南/西司他丁显示非劣效性。
- APEKS-NP中头孢地尔治疗医院获得性肺炎对美罗培南显示非劣效性。
- CREDIBLE-CR中头孢地尔治疗革兰阴性菌所致严重感染的全因死亡率高于最佳可用治疗,主要见于不动杆菌属感染患者亚组。
关键数值与推荐
- 美国FDA于2020年9月28日批准头孢地尔用于治疗医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎。
临床怎么用
- 头孢地尔可用于治疗多重耐药革兰阴性菌所致复杂性尿路感染及医院获得性/呼吸机相关性细菌性肺炎。
- 治疗革兰阴性菌所致严重感染尤其是不动杆菌属感染时,应权衡头孢地尔治疗与最佳可用治疗的全因死亡率差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cefiderocol is a novel siderophore cephalosporin that forms a complex with extracellular free ferric iron, which leads to transportation across the outer cell membrane to exert its bactericidal activity through cell wall synthesis inhibition. This pharmacological property has rendered cefiderocol active against several clinically relevant MDR Gram-negative bacteria as evidenced by several in vitro and in vivo studies. Cefiderocol was first approved by the US FDA on 14 November 2019 for the treatment of complicated urinary tract infections. On 28 September 2020, cefiderocol was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The FDA-approved indications are based on clinical data from the APEKS-cUTI, APEKS-NP and CREDIBLE-CR trials. In APEKS-cUTI, cefiderocol demonstrated non-inferiority to imipenem/cilastatin for the treatment of complicated urinary tract infection caused by MDR Gram-negative bacteria. In APEKS-NP, cefiderocol demonstrated non-inferiority to meropenem for treatment of nosocomial pneumonia. However, in CREDIBLE-CR, higher all-cause mortality was observed with cefiderocol compared with best available therapy for the treatment of severe infections caused by Gram-negative bacteria, primarily in the subset of patients with Acinetobacter spp. infections. Several case reports/series have demonstrated clinical success with cefiderocol for a variety of severe infections. The purpose of this article is to review available data on the mechanism of action, in vitro and in vivo data, pharmacokinetics, pharmacodynamics, susceptibility testing, efficacy and safety of cefiderocol to address its role in therapy.
引用
- Parsels KA, Mastro KA, Steele JM, et al. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother. 2021. PMID: 33532823. doi:10.1093/jac/dkab015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。